Annual report pursuant to Section 13 and 15(d)

SPONSORED RESEARCH AND LICENSE AGREEMENTS (Details)

v3.3.1.900
SPONSORED RESEARCH AND LICENSE AGREEMENTS (Details) - USD ($)
1 Months Ended 12 Months Ended
Sep. 30, 2015
Mar. 31, 2015
Dec. 31, 2015
Collaborative Arrangement      
Collaborations      
Maximum amount of contingent payments receivable     $ 533,600,000
Specified Development Events | Collaborative Arrangement      
Collaborations      
Maximum amount of contingent payments receivable     150,500,000
Specified Regulatory Events | Collaborative Arrangement      
Collaborations      
Maximum amount of contingent payments receivable     345,600,000
Specified Product Launch Events | Collaborative Arrangement      
Collaborations      
Maximum amount of contingent payments receivable     37,500,000
Bristol-Myers Squibb Company      
Collaborations      
Upfront fee received   $ 30,000,000  
Deferred revenue related to upfront payment   $ 30,000,000 13,400,000
Revenue recognized     16,600,000
Bristol-Myers Squibb Company | Research Activities      
Collaborations      
Revenue recognized     822,000
Bristol-Myers Squibb Company | Minimum      
Collaborations      
Contingent payments     309,000,000
Aclaris      
Collaborations      
Upfront fee received $ 8,000,000    
Contingent payments     80,000,000
Revenue recognized     $ 8,000,000